A Novel Indicator of Myocardial Injury after Acute Myocardial Infarction: 'DPP-3'

BackgroundDipeptidyl peptidase 3 (DPP-3) is an intracellular enzyme that causes hemodynamic instability and cardiac depression in several cases such as cardiogenic shock, sepsis and burns where DPP-3 is released into the blood due to cell death. Data on the effect of higher DPP-3 levels on acute coronary syndrome (ACS) patients are currently lacking. The aim of this study was to evaluate the effect of DPP-3 levels on ACS patients. MethodsIn this prospective study, we included ACS patients including STEMI and non-STEMI groups and a control group to compare various demographic, echocardiographic and laboratory parameters including DPP-3. DPP-3 levels were measured at 24(th), 48(th), and 72(nd) h from the onset of symptoms in ACS patients and then compared with left ventricle ejection fraction (LVEF) for the assessment of left ventricle systolic function. ResultsA total of 70 ACS patients (age 62.5 +/- 11 years, 68.6% male) were recruited and 48 normal individuals were included as control group (age 61.1 +/- 10 years, 66.7% male). It has been demonstrated that DPP-3 levels are significantly higher in the ACS group than the control group like troponin I levels. DPP-3 levels were found to be one of the independent predictors of LVEF similar to NT-proBNP and troponin I. ConclusionsThis study suggests that DPP-3 could be an important indicator of myocardial depression predicting left ventricle systolic function in ACS.